Tumores neuroendocrinos: impacto de LANREÓTIDA en la supervivencia de la enfermedad estable y progresiva - page 22

mPFS 12,9 m

Lanreótido 120 mg

cada 28 días

Martín-Richard M, et al.

BMC Cancer

2013

EFFICACY OF LANREOTIDE IN PROGRESSIVE DISEASE

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,12,13,14,15,16,17,18,19,20,21 23,24,25,26